Cargando…

Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial

The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-based treatment intensification over continued standard therapy with CHOP (plus rituximab (R) in CD20-positive lymphomas). We hypothesized that PET analysis of all lymphoma manifestations may identify patients who b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seifert, Robert, Kersting, David, Rischpler, Christoph, Sandach, Patrick, Ferdinandus, Justin, Fendler, Wolfgang P., Rahbar, Kambiz, Weckesser, Matthias, Umutlu, Lale, Hanoun, Christine, Hüttmann, Andreas, Reinhardt, Hans Christian, von Tresckow, Bastian, Herrmann, Ken, Dührsen, Ulrich, Schäfers, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712103/ https://www.ncbi.nlm.nih.gov/pubmed/36241697 http://dx.doi.org/10.1038/s41375-022-01713-y

Ejemplares similares

Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer
por: Weber, Manuel, et al.
Publicado: (2021)

Silicon-photomultiplier-based PET/CT reduces the minimum detectable activity of iodine-124
por: Kersting, David, et al.
Publicado: (2021)

Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617
por: Kessel, Katharina, et al.
Publicado: (2019)

Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Do fasting or high caloric drinks affect the physiological uptake of fluorine-18 prostate-specific membrane antigen-1007 in liver and bowel?
por: Rahbar, Kambiz, et al.
Publicado: (2019)

First experiences with dynamic renal [(68)Ga]Ga-DOTA PET/CT: a comparison to renal scintigraphy and compartmental modelling to non-invasively estimate the glomerular filtration rate
por: Kersting, David, et al.
Publicado: (2022)

Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial
por: Broecker-Preuss, Martina, et al.
Publicado: (2021)

Atypical bilateral ventilation/perfusion mismatches in an asymptomatic patient suffering from metastatic thyroid cancer
por: Kersting, David, et al.
Publicado: (2021)

PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
por: Seifert, Robert, et al.
Publicado: (2020)

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Seifert, Robert, et al.
Publicado: (2020)

Evaluation of (18)F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision
por: Weber, Manuel, et al.
Publicado: (2021)

Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma
por: Johansson, Patricia, et al.
Publicado: (2023)

Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome
por: Richter, Julia, et al.
Publicado: (2019)

Phantom-based acquisition time and image reconstruction parameter optimisation for oncologic FDG PET/CT examinations using a digital system
por: Fragoso Costa, Pedro, et al.
Publicado: (2022)

Comparing lesion detection efficacy and image quality across different PET system generations to optimize the iodine-124 PET protocol for recurrent thyroid cancer
por: Kersting, David, et al.
Publicado: (2021)

Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy
por: Seifert, Robert, et al.
Publicado: (2021)

Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management
por: Roll, Wolfgang, et al.
Publicado: (2021)

Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphoma
por: Kurch, Lars, et al.
Publicado: (2021)

Repeatability of (68)Ga-PSMA-HBED-CC PET/CT–Derived Total Molecular Tumor Volume
por: Seifert, Robert, et al.
Publicado: (2022)

Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from (68)Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient
por: Weber, Manuel, et al.
Publicado: (2020)

Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
por: Ferdinandus, Justin, et al.
Publicado: (2022)

Radioligand therapy using [(177)Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
por: Seifert, Robert, et al.
Publicado: (2020)

Predictive Factors for RAI-Refractory Disease and Short Overall Survival in PDTC
por: Kersting, David, et al.
Publicado: (2021)

Artificial intelligence guided enhancement of digital PET: scans as fast as CT?
por: Hosch, René, et al.
Publicado: (2022)

Response to letter to the editor
por: Kersting, David, et al.
Publicado: (2022)

Safety and Efficacy of (90)Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
por: Fendler, Wolfgang P., et al.
Publicado: (2022)

Early report on the severity of COVID‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant
por: Ullrich, Fabian, et al.
Publicado: (2022)

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Kessel, Katharina, et al.
Publicado: (2020)

Evaluation of (68)Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving (177)Lu-PSMA-617 Therapy: A Radiomics Analysis
por: Roll, Wolfgang, et al.
Publicado: (2021)

Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging
por: Kessel, Katharina, et al.
Publicado: (2021)

Time to Treatment Intensification to Reduce Diabetes-Related Complications: A Post Hoc Study
por: Kaewbut, Piranee, et al.
Publicado: (2022)

Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy
por: Ferdinandus, Justin, et al.
Publicado: (2021)

Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
por: Voltin, Conrad-Amadeus, et al.
Publicado: (2023)

N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [(18)F]FDG PET/CT compared to the histopathology reference standard
por: Hautzel, Hubertus, et al.
Publicado: (2021)

Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling
por: Siebermair, J., et al.
Publicado: (2020)

Incremental diagnostic value of [(18)F]tetrafluoroborate PET-CT compared to [(131)I]iodine scintigraphy in recurrent differentiated thyroid cancer
por: Dittmann, Matthias, et al.
Publicado: (2020)

Time after Synthesis and Time after Injection Do Not Affect Diagnostic Quality of [(18)F]F-PSMA 1007 PET
por: Relt, Elisabeth, et al.
Publicado: (2022)

Supporting data for positron emission tomography-based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determination
por: Schmitz, Christine, et al.
Publicado: (2019)

(18)F-flutemetamol positron emission tomography in cardiac amyloidosis
por: Papathanasiou, Maria, et al.
Publicado: (2020)

[(68)Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas
por: Guberina, Nika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k9nkl54olvb54qm0dgb2q2mlko